Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: SEC-2012.1.5-1 | Award Amount: 36.02M | Year: 2013
The accidental or deliberate release of CBRNE materials are low probability events that can have a significant impact on citizens and society. Whenever and wherever they occur, they usually require a gradual and multi-facetted response as they tend to provoke severe and unexpected physical, psychological, societal, economical and political effects that cross EU-borders. Successful CBRNE resilience requires a global System-of-Systems approach. The EDEN project will leverage the added-value of tools and systems from previous R&D efforts and improve CBRNE resilience through their adaptation and integration. The concept of the EDEN project is to provide a toolbox of toolboxes EDEN Store to give stakeholders access to interoperable capabilities they deem important, or affordable, from a certified set of applications. It will share the burden of development and allows for lessons to be learned and applications to be enhanced. The benefit of the EDEN concept is that integration will be applied at the application level. This means that all countries and stakeholders, irrespective of their existing capability levels, will gain immediate advantages through improved interoperability. EDEN Store will allow capabilities to be shared among multi-national CBRNE stakeholders, which is paramount in cross-border incident management, and through time allow for a build up of common capability across European boundaries. EDEN will be validated by three themed end-user demonstrations (Food Industry, Multi Chemical, Radiological) covering multiple hazards (CBRNE), phases of the security cycle, response tiers, and stakeholders. The EDEN consortium includes CBRNE domain end-users, major stakeholders, large system integration and solution providers, including SMEs with innovative solutions, and RTOs. The impact of EDEN is to provide affordable CBRNE resilience and market sustainability through the better integration of systems in real operations and thus enhancing the safety of citizens.
Agency: Cordis | Branch: FP7 | Program: CP | Phase: ICT-2013.3.3 | Award Amount: 5.30M | Year: 2014
Through further development, integration and validation of micro-nano-bio and biophotonics systems from previous projects CanDo will develop an instrument that will permit the identification and concentration determination of rare cells in peripheral blood for two key societal challenges, early and low cost anti-cancer drug efficacy determination and cancer diagnosis/monitoring.A cellular link between the primary malignant tumor and the peripheral metastases, responsible for 90% of cancer-related deaths, has been established in the form of circulating tumor cells (CTCs) in peripheral blood. Furthermore the relatively short survival time of CTCs in peripheral blood means that their detection is indicative of tumor progression thereby providing in addition to a prognostic value an evaluation of therapeutic efficacy and early recognition of tumor progression in theranostics. In cancer patients however blood concentrations are very low (=1 CTC/1E9 cells) and current detection strategies are too insensitive, limiting use to prognosis of only those with advanced metastatic cancer. Similarly problems occur in therapeutics with anti-cancer drug development leading to lengthy and costly trials often preventing access to market. There is therefore a clear need for a novel analytical platform capable of highly reproducible and reliable identification of CTC concentrations of interest in an easily accessible format.With all relevant industrial stakeholders and users onboard CanDo is uniquely capable of delivering such a platform. Its novel cell separation/SERS analysis technologies plus nucleic acid based molecular characterization will provide an accurate CTC count with high throughput and high yield meeting both key societal challenges. Being beyond the state of art it will lead to substantial share gains not just in the high end markets of drug discovery and cancer diagnostics but due to modular technologies in others e.g. transport, security and safety and environment.
Microfluidic ChipShop GmbH | Date: 2013-03-11
The present invention describes a device consisting of a rotor, a holding-down device, and a base plate. The base plate is normally a fluidic system, a planar fluidic system for example or a fluidic system with several fluidic ports for a directed guidance of liquids or gases through different channels, channel systems, cavities or tubing, for the combination liquid and gas streams, or for prevention of liquid flows.
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: NMP.2012.1.4-2 | Award Amount: 4.86M | Year: 2013
The Self-Assembled Virus-like Vectors for Stem Cell Phenotyping (SAVVY) project relies on hierarchical, multi-scale assembly of intrinsically dissimilar nanoparticles to develop novel types of multifunctional Raman probes for analysis and phenotyping of heterogeneous stem cell populations. Our project will address a large unmet need, as stem cells have great potential for a broad range of therapeutic and biotechnological applications. Characterization and sorting of heterogeneous stem cell populations has been intrinsically hampered by (1) lack of specific antibodies, (2) need for fluorescence markers, (3) low concentration of stem cells, (4) low efficiencies/high costs. Our technology will use a fundamentally different approach that (1) does not require antibodies, aptamers, or biomarkers, (2) is fluorescence-label free, and (3) is scalable at acceptable cost. The approach uses intrinsic differences in the composition of membranes of cells to distinguish cell populations. These differences will be detect by SERS and analysed through multicomponent analysis. We have combined the necessary expertise to tackle this challenge: Stellacci has developed rippled nanoparticles that specifically interact with and adhere to cell membranes (analogues to cell penetrating peptides). Lahann has developed bicompartmental Janus polymer particles that have already been surface-modified with rippled particles and integrate specifically in the cell membrane (analogues to viruses). Liz-Marzan has developed highly Raman-active nanoparticles and has demonstrated their selectivity and specificity in SERS experiments. These Raman probes will be loaded into the synthetic viruses to enable membrane fingerprinting. Stevens has developed a Bioinformatics platform for fingerprinting of stem cell populations using cluster analysis algorithms. The effort will be joined by two SMEs, ChipShop and OMT, that will be able to develop the necessary microfluidic and Raman detection hardware.
Agency: Cordis | Branch: FP7 | Program: MC-ITN | Phase: FP7-PEOPLE-2013-ITN | Award Amount: 3.98M | Year: 2013
The objective is to deliver a trans-European network of industrially oriented specialists fully trained in the development and application of microbioreactor (MBR) technology to support development of innovative bio-based manufacturing processes. The specialistis will be trained by leaders in the field and with state of the art equipment and methodologies. MBRs are a promising tool for screening and scale-up of fermentation and biocatalysis processes due to their low production cost, small working volumes, flexibility and their potential for information-rich experiments under well-controlled experimental conditions. In this consortium, we will further develop MBRs for chemical and biochemical screening, paying special attention to MBR parallelization and applicability for different applications. In addition, characterization of experimental uncertainty, development of reactant feeding strategies at micro-scale and coupling of microscale experimentation to automated design of experiments (DoE) will document applicability of MBRs for chemical and biochemical research. To enhance the applicability of microfluidic enzymatic reactors for organic synthesis, we will establish microfluidic chemo-biocatalytic reaction systems that enable rapid characterization of biosynthetic pathways and chemo-enzymatic conversions. This will be underpinned with immobilization methods that permit rapid and reversible binding of a range of biocatalysts and modeling that relates the kinetic data with results from larger scales. Complemented with precisely positioned fluorescence-based sensor arrays, novel nanosensor particle concepts, and integrated Raman and NIR probes, the MBRs will deliver the data-rich experimentation needed for industrial applications. Data processing and information management will be accomplished by developing CFD and mathematical modeling methods that permit prediction and interpretation of fermentation and biocatalytic processes in MBRs.